D G Shah

Stakeholders have failed to collaborate with the pharma industry to ensure universal access and minimum price controls. Instead, they are working in tandem to restore the regime of rigorous restrictio

USFDA's zero tolerance policy requires our drug firms to reorient not just processes but organisational cultures to serve that market credibly